FOSCARNET AND GANCICLOVIR PHARMACOKINETICS DURING CONCOMITANT OR ALTERNATING MAINTENANCE THERAPY FOR AIDS-RELATED CYTOMEGALOVIRUS RETINITIS

被引:10
作者
AWEEKA, FT
GAMBERTOGLIO, JG
KRAMER, F
VANDERHORST, C
POLSKY, B
JAYEWARDENE, A
LIZAK, P
EMRICK, L
TONG, W
JACOBSON, MA
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143
[2] SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110
[3] UNIV SO CALIF,LOS ANGELES CTY MED CTR,LOS ANGELES,CA 90033
[4] UNIV N CAROLINA,DEPT MED,DIV INFECT DIS,CHAPEL HILL,NC
[5] MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021
[6] MEM SLOAN KETTERING CANC CTR,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021
关键词
D O I
10.1016/0009-9236(95)90209-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The use of foscarnet and ganciclovir as a combination treatment for cytomegalovirus retinitis is increasing because of limitations associated with single agent therapy. Methods: The pharmacokinetics of foscarnet and ganciclovir were determined in 13 patients receiving either concomitant therapy (regimen A) or daily alternating therapy (regimen B) for maintenance of cytomegalovirus disease. For regimen A, 60 mg/kg intravenous foscarnet and 3.75 mg/kg ganciclovir were sequentially administered daily; for regimen B, 120 mg/kg foscarnet and 6 mg/kg ganciclovir were administered on alternating days. For both regimens, serial blood sampling for pharmacokinetic analysis was performed for each drug alone (day 1 or 2) and after 2 weeks of combination therapy. Plasma samples for foscarnet and ganciclovir analysis were performed by means of high-performance liquid chromatography, Pharmacokinetic analysis was performed with noncompartmental methods. Results: For regimen A, the plasma clearance (CL) of foscarnet did not change in the presence of ganciclovir, averaging 0.12 +/- 0.08 and 0.11 +/- 0.02 L/hr/kg on study days 2 and 14, respectively (p = 0.34). The volume of distribution (V-ss) and mean residence time (MRT) also did not change significantly. CL and MRT of foscarnet did not change for regimen B, although a slight increase in V-ss was observed before (0.38 +/- 0.05 L/kg) and after (0.46 +/- 0.07 L/kg) alternating therapy (p = 0.03). Ganciclovir CL did not change for either regimen, with mean values of 0.21 +/- 0.10 and 0.25 +/- 0.10 L/hr/kg (regimen A,p = 0.17) and 0.32 +/- 0.10 and 0.34 +/- 0.11 L/hr/kg (regimen B, p = 0.24). MRT and V-ss were also not significantly different. Conclusion: These plasma data suggest that further dosage adjustments are unneccessary for concomitant or alternating maintenance therapy.
引用
收藏
页码:403 / 412
页数:10
相关论文
共 26 条
[1]   PHARMACOKINETICS OF INTERMITTENTLY ADMINISTERED INTRAVENOUS FOSCARNET IN THE TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME PATIENTS WITH SERIOUS CYTOMEGALO-VIRUS RETINITIS [J].
AWEEKA, F ;
GAMBERTOGLIO, J ;
MILLS, J ;
JACOBSON, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :742-745
[2]   PHARMACOKINETICS OF CONCOMITANTLY ADMINISTERED FOSCARNET AND ZIDOVUDINE FOR TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION (AIDS CLINICAL-TRIALS GROUP PROTOCOL-053) [J].
AWEEKA, FT ;
GAMBERTOGLIO, JG ;
VANDERHORST, C ;
RAASCH, R ;
JACOBSON, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1773-1778
[3]   TREATMENT OF AGGRESSIVE CYTOMEGALOVIRUS RETINITIS WITH GANCICLOVIR IN COMBINATION WITH FOSCARNET IN A CHILD INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BUTLER, KM ;
DESMET, MD ;
HUSSON, RN ;
MUELLER, B ;
MANJUNATH, K ;
MONTRELLA, K ;
LOVATO, G ;
JAROSINSKI, P ;
NUSSENBLATT, RB ;
PIZZO, PA .
JOURNAL OF PEDIATRICS, 1992, 120 (03) :483-486
[4]   CONCURRENT USE OF GANCICLOVIR AND FOSCARNET TO TREAT CYTOMEGALOVIRUS-INFECTION IN AIDS PATIENTS [J].
DIETERICH, DT ;
POLES, MA ;
LEW, EA ;
MENDEZ, PE ;
MURPHY, R ;
ADDESSI, A ;
HOLBROOK, JT ;
NAUGHTON, K ;
FRIEDBERG, DN .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05) :1184-1188
[5]   PREVALENCE OF RESISTANCE IN PATIENTS RECEIVING GANCICLOVIR FOR SERIOUS CYTOMEGALOVIRUS-INFECTION [J].
DREW, WL ;
MINER, RC ;
BUSCH, DF ;
FOLLANSBEE, SE ;
GULLETT, J ;
MEHALKO, SG ;
GORDON, SM ;
OWEN, WF ;
MATTHEWS, TR ;
BUHLES, WC ;
DEARMOND, B .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :716-719
[6]   GANCICLOVIR FOSCARNET FOR CYTOMEGALOVIRUS MENINGOENCEPHALITIS IN AIDS [J].
ENTING, R ;
DEGANS, J ;
REISS, P ;
JANSEN, C ;
PORTEGIES, P .
LANCET, 1992, 340 (8818) :559-560
[7]   COMBINATIONS OF 3'-AZIDO-3'-DEOXYTHYMIDINE (ZIDOVUDINE) AND PHOSPHONOFORMATE (FOSCARNET) AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 AND CYTOMEGALO-VIRUS REPLICATION INVITRO [J].
ERIKSSON, BFH ;
SCHINAZI, RF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :663-669
[8]   HUMAN PHARMACOKINETICS OF THE ANTIVIRAL DRUG DHPG [J].
FLETCHER, C ;
SAWCHUK, R ;
CHINNOCK, B ;
DEMIRANDA, P ;
BALFOUR, HH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) :281-286
[9]  
FLORESAGUILAR M, 1993, OPHTHALMOLOGY, V100, P1022
[10]   INCREASED EFFICACY OF GANCICLOVIR IN COMBINATION WITH FOSCARNET AGAINST CYTOMEGALOVIRUS AND HERPES-SIMPLEX VIRUS TYPE-2 INVITRO AND INVIVO [J].
FREITAS, VR ;
FRASERSMITH, EB ;
MATTHEWS, TR .
ANTIVIRAL RESEARCH, 1989, 12 (04) :205-212